Palisade Bio (PALI) Return on Sales (2011 - 2026)

Palisade Bio (PALI) posted quarterly Return on Sales of 1.95% for Q4 2023, up 1.4% quarter-over-quarter from 1.98% in Q3 2023.

Palisade Bio (PALI) Return on Sales (2011 - 2026) Analysis & Trends

Palisade Bio (PALI) has reported Return on Sales for 12 consecutive years, with 1.95% the latest figure, recorded in Q4 2023.

In Q4 2023, Return on Sales changed N/A year-over-year to 1.95%; the TTM figure through Dec 2023 stood at 1.95% (changed N/A YoY), while the FY2023 annual figure was 1.68%, changed N/A from the prior year.
Return on Sales advanced to 1.95% in Q4 2023 per PALI's latest filing, from 1.98% in the prior quarter.
Across five years, Return on Sales topped out at 1.53% in Q1 2023 and bottomed at 56.25% in Q1 2022.
Historically, Return on Sales has averaged 13.71% across 4 years, with a median of 7.6% in 2020.
Annual changes were most pronounced in 2020 — Return on Sales sank 524 bps — and 2023, when it soared 5472 bps.
Palisade Bio's Return on Sales stood at 8.5% in 2019, then plunged by 62 bps to 13.74% in 2020, then sank by 301 bps to 55.05% in 2022, then surged by 96 bps to 1.95% in 2023.
Business Quant data shows PALI's Return on Sales at 1.95% in Q4 2023, 1.98% in Q3 2023, and 2.01% in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.00%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	0.00%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.00%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	0.00%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.00%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.00%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.00%
10	Palisade Bio	372.94 Mn	247.74 Mn	-	-0.23%

Download Data